INTRODUCTION

The academician is the life line of any medical college, hospital or university as he/she performs the quadruple functions of patient care, teaching, administration and research. While all of these can provide a great measure of satisfaction, a key driver to satiating intellectual curiosity remains research. Good research contributes to evidence-based medicine and thus better and improved patient care with the ultimate goal of promoting health.

Research, however, is a laborious, time and labour intensive task that can take months or even years to reach fruition. Drug development research, in particular, is long and arduous and bringing a single new drug costs on an average USD 1.78 billion and takes approximately 13.5 years from discovery to the market.[1] Drug development research is primarily funded by the pharmaceutical industry including the process of human testing (Phase I-IV studies). These studies (called clinical trials or regulatory studies) are conducted with the academician as the principal investigator largely in academic centres. The pharmaceutical industry funds or ‘sponsors’ the studies and ensures compliance with the country’s regulatory requirements. Academicians, however, also carry out their own research and these studies are called as ‘Investigator-initiated studies’ (IISs). Here, the academician raises funds for the study through his efforts from various sources including possibly the pharmaceutical industry. In these IISs, he dons the dual mantle of an investigator and ‘sponsor’ and thus directly becomes responsible for ensuring regulatory compliance.

Anaesthesia as a speciality straddles several diverse disciplines that include various branches of surgery and medicine as well as critical care and pain management among others. The past three decades have also seen remarkable advances in the field of anaesthesia, some of which include pulse oximetry.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Gogtay NJ, Ravi R, Thatte UM. Regulatory requirements for clinical trials in India: What academicians need to know. Indian J Anaesth 2017;61:192-9.
end-tidal gas monitoring, introduction of propofol and the laryngeal mask airway. Anaesthesiologists are uniquely positioned to carry out translational research given the data-rich environment in which they practice[2] and this research can be used successfully to guide evidence-based practice of the discipline as also public health policy.[3] Regardless of the nature of the research (Regulatory Clinical Trials or IISs), knowledge of the regulatory requirements is an essential imperative for researchers. The present article details these requirements giving their historical evolution, the key bodies in India that govern or oversee research along with ‘must know’ and ‘good to know’ for the conduct of clinical trials in the country.

THE NATIONAL REGULATORY BODY - THE CENTRAL DRUGS STANDARD CONTROL ORGANISATION AND THE DRUGS CONTROLLER GENERAL OF INDIA

The Central Drugs Standard Control Organization (CDSCO) is the National Regulatory Authority in India. Its equivalent counterparts elsewhere include the United States Food and Drug Administration (US FDA), Health Canada and the European Medicines Agency. CDSCO is an arm of the Ministry of Health and Family Welfare, Government of India. Its mission is to safeguard and enhance public health by assuring the safety, efficacy and quality of drugs, cosmetics and medical devices.[4]

The Drugs Controller General of India (DCGI) is an official of the CDSCO who is the final regulatory authority for the approval of clinical trials in the country. His ambit, in addition, also extends to inspections of trial sites, inspections of sponsors of clinical research and manufacturing facilities in the country, oversight of the Central Drugs Testing Laboratory (Mumbai) and the Regional Drugs Testing Laboratory as also heading the Indian Pharmacopeia Commission among various other roles, responsibilities and functions.

THE DEPARTMENT OF HEALTH RESEARCH AND THE INDIAN COUNCIL OF MEDICAL RESEARCH

The Indian Council of Medical Research (ICMR) is the apex body that is responsible for the formulation, coordination and promotion of biomedical research. It receives funding from the Ministry of Health and Family Welfare and the Department of Health Research, Government of India.[5]
in India to be conducted in the same phase of drug development as elsewhere in the world, demarcation of clear roles and responsibilities of the sponsor, investigator and ECs, underscoring the importance of informed consent, requirement for studies in special populations and mandating that protocol amendments need approval from the office of the DCGI. Over the next 10 years, a slew of changes and reforms dotted the regulatory landscape as outlined in Table 1.

### Table 1: Evolution of regulatory changes in India (2005–2016 as relevant to clinical trials)

<table>
<thead>
<tr>
<th>G.S.R./notification number with year/date</th>
<th>Nature of the amendment/gazette notification/regulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>G.S.R. 32 (E) dated 20th January, 2005, IInd amendment</td>
<td>Amendment of 1988 version of Schedule Y. Key features - definition of a clinical trial and clear identification of responsibilities of sponsor, investigator and ECs and permitting clinical trials to be conducted in the same phase as elsewhere in the world</td>
</tr>
<tr>
<td>SO 1468 (E) dated 6th October, 2005</td>
<td>Devices such as cardiac stents, heart valves, intravenous cannulas, catheters, orthopedic implants and internal prosthetic replacements specified as drugs</td>
</tr>
<tr>
<td>ICMR guideline Dated October, 2006</td>
<td>The second revision of the guideline that is valid until today. The next revision is expected in 2017</td>
</tr>
<tr>
<td>G.S.R. 53 (E) dated 30th January, 2013</td>
<td>• Introduction of compensation for clinical trial related injury or death</td>
</tr>
<tr>
<td>G.S.R. 63 (E) dated 1st February, 2013</td>
<td>• Introduction of SAE analysis and timelines for reporting SAEs</td>
</tr>
<tr>
<td>G.S.R. 72 (E) dated 8th February, 2013</td>
<td>• Specifies various requirements conditions for conduct of clinical trials (for example IEC approval, registration with CTRI, submission of annual status report)</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Registration of ECs with DCGI made mandatory</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Introduction of AV recording of informed consent process of clinical trials</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Cap on the number of trials that could be conducted by an Investigator to three only (n=3)</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Clinical trial waiver for approval of new drugs already approved outside India specified under certain conditions – national emergency, extreme urgency, epidemic and orphan drugs and drugs indicated for diseases in which no therapy exists</td>
</tr>
<tr>
<td>File no, ECR/Misc/Indt EC/007/2013 dated 30th July 2013</td>
<td>Medical devices may not need Phase 1 studies. However, the process of their clinical trials approval should be similar to that of drugs or vaccines</td>
</tr>
<tr>
<td>G.S.R. 889 (E) dated 12th December, 2014 effective June 2015</td>
<td>When placebos are used, the trial design should be appropriate, efficient and ethical</td>
</tr>
<tr>
<td>G.S.R. 611 (E) dated 31th July, 2015</td>
<td>Independent ECs registered by CDSCO to oversee Bioavailability and Bioequivalence studies only</td>
</tr>
<tr>
<td>G.S.R. 313 (E) dated 16th March, 2016</td>
<td>• Clarification regarding compensation and free medical management in case of trial related injury given</td>
</tr>
<tr>
<td>DGFT notification dated 4th August, 2016</td>
<td>• Change in timelines for SAE reporting</td>
</tr>
<tr>
<td>Circular by CDSCO; dated 2nd August, 2016</td>
<td>Modification and relaxation of AV consenting norms – for vulnerable populations only and where a NCE or NME is being studied</td>
</tr>
<tr>
<td>File 12-01/14- Pt 47, dated 2nd August, 2016</td>
<td>A ‘new’ drug undergoing a clinical trial for investigator initiated studies (IIS) no longer needs approval from the DCGI. Approval from the IEC would suffice</td>
</tr>
<tr>
<td>Circular by CDSCO; dated 3rd August, 2016</td>
<td>Indian diagnostic laboratories and research centres can import/export biological material without the need for an import/export license. They only need to submit an undertaking about the safe transfer and disposal of the biological material to the Customs at the port of entry/exit</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>The only three trials per investigator norm revoked</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>The condition that trials could not be conducted at sites with less than 50 beds revoked</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>No approval needed from DCGI for addition of new trial site or investigator, only IEC permission is required</td>
</tr>
</tbody>
</table>

### A - Regulatory definitions

**What is a ‘clinical trial’**

A clinical trial is defined as the systematic study of new drug(s) (see below for the definition of a new drug) in human subject(s) to generate data for discovering and/or verifying:

- **New chemical entity (NCE)**
- **New molecular entity (NME)**
- **Serious adverse events (SAEs)**
- **Institutional Ethics Committee (IEC)**
- **Audio visual (AV)**
- **Drug Controller General of India (DCGI)**
- **Directorate General of Foreign Trade (DGFT)**
- **New Chemical Entity (NCE)**
- **New Molecular Entity (NME)**
- **Serious Adverse Events (SAEs)**

---

**Table 1**

<table>
<thead>
<tr>
<th>G.S.R./notification number with year/date</th>
<th>Nature of the amendment/gazette notification/regulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>G.S.R. 32 (E) dated 20th January, 2005, IInd amendment</td>
<td>Amendment of 1988 version of Schedule Y. Key features - definition of a clinical trial and clear identification of responsibilities of sponsor, investigator and ECs and permitting clinical trials to be conducted in the same phase as elsewhere in the world</td>
</tr>
<tr>
<td>SO 1468 (E) dated 6th October, 2005</td>
<td>Devices such as cardiac stents, heart valves, intravenous cannulas, catheters, orthopedic implants and internal prosthetic replacements specified as drugs</td>
</tr>
<tr>
<td>ICMR guideline Dated October, 2006</td>
<td>The second revision of the guideline that is valid until today. The next revision is expected in 2017</td>
</tr>
<tr>
<td>G.S.R. 53 (E) dated 30th January, 2013</td>
<td>• Introduction of compensation for clinical trial related injury or death</td>
</tr>
<tr>
<td>G.S.R. 63 (E) dated 1st February, 2013</td>
<td>• Introduction of SAE analysis and timelines for reporting SAEs</td>
</tr>
<tr>
<td>G.S.R. 72 (E) dated 8th February, 2013</td>
<td>• Specifies various requirements conditions for conduct of clinical trials (for example IEC approval, registration with CTRI, submission of annual status report)</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Registration of ECs with DCGI made mandatory</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Introduction of AV recording of informed consent process of clinical trials</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Cap on the number of trials that could be conducted by an Investigator to three only (n=3)</td>
</tr>
<tr>
<td>File no 12-01/14-DC Pt 47, dated 3rd July, 2014</td>
<td>Clinical trial waiver for approval of new drugs already approved outside India specified under certain conditions – national emergency, extreme urgency, epidemic and orphan drugs and drugs indicated for diseases in which no therapy exists</td>
</tr>
<tr>
<td>File no, ECR/Misc/Indt EC/007/2013 dated 30th July 2013</td>
<td>Medical devices may not need Phase 1 studies. However, the process of their clinical trials approval should be similar to that of drugs or vaccines</td>
</tr>
<tr>
<td>G.S.R. 889 (E) dated 12th December, 2014 effective June 2015</td>
<td>When placebos are used, the trial design should be appropriate, efficient and ethical</td>
</tr>
<tr>
<td>G.S.R. 611 (E) dated 31th July, 2015</td>
<td>Independent ECs registered by CDSCO to oversee Bioavailability and Bioequivalence studies only</td>
</tr>
<tr>
<td>G.S.R. 313 (E) dated 16th March, 2016</td>
<td>• Clarification regarding compensation and free medical management in case of trial related injury given</td>
</tr>
<tr>
<td>DGFT notification dated 4th August, 2016</td>
<td>• Change in timelines for SAE reporting</td>
</tr>
<tr>
<td>Circular by CDSCO; dated 2nd August, 2016</td>
<td>Modification and relaxation of AV consenting norms – for vulnerable populations only and where a NCE or NME is being studied</td>
</tr>
<tr>
<td>File 12-01/14- Pt 47, dated 2nd August, 2016</td>
<td>A ‘new’ drug undergoing a clinical trial for investigator initiated studies (IIS) no longer needs approval from the DCGI. Approval from the IEC would suffice</td>
</tr>
<tr>
<td>Circular by CDSCO; dated 3rd August, 2016</td>
<td>Indian diagnostic laboratories and research centres can import/export biological material without the need for an import/export license. They only need to submit an undertaking about the safe transfer and disposal of the biological material to the Customs at the port of entry/exit</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>The only three trials per investigator norm revoked</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>The condition that trials could not be conducted at sites with less than 50 beds revoked</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>No approval needed from DCGI for addition of new trial site or investigator, only IEC permission is required</td>
</tr>
<tr>
<td>Notice by CDSCO; 5th October, 2016 (CDSCO/IT/2015-[48])</td>
<td>‘SUGAM’ portal for online applications for clinical trials as part of efforts to increase the transparency, and efficiency of processing clinical trial applications</td>
</tr>
</tbody>
</table>
• The clinical pharmacological (including pharmacodynamic and pharmacokinetic) effects
• And/or adverse effects
• With the objective of determining safety and/or efficacy of the new drug

What is a 'new drug'
A ‘new’ drug\[12\] is one:
• That has not been used to a significant extent in the country
• An already approved drug that is now proposed to be used in a different dosage, different dosage form, a new route or a new indication. An example of this would be the intrathecal or epidural route of use of dexmedetomidine
• Approved for use but has been on the market for <4 years after approval
• A fixed-dose combination of two or more drugs, individually approved earlier for certain claims, which are now proposed to be combined for the first time in a fixed ratio
• All vaccines
• Drugs made using the recombinant DNA technology

B - Conduct of the clinical trial

Conduct of the clinical trial
The investigator must ensure that clinical trials are conducted as per the rules outlined below[13]
• In compliance with an EC and a DCGI approved protocol
• In the case of IISs with ‘new drugs’, DCGI approval is no longer needed; only an EC approval is required – 16th March, 2016 G.S.R. 313 (E)[14]
• In compliance with GCP guidelines
• All applicable regulations

Registration of Ethics Committees that approve studies (Rule 122DD)[15]
• Investigators and Administrators of Academic Institutes should ensure that their Institutional Ethics Committees (IECs) are registered with the central licensing authority and the registration renewed at the end of 3 years.\[15\] This is mandatory for Regulatory Clinical Trials

Approval from Institutional Ethics Committee
• All clinical trials need to have approval from the IEC
• A recent regulatory change with respect to IISs is that academicians who carry out trials with ‘new drugs’ no longer need approval from the DCGI for the conduct of the trial and IEC approval would suffice. This is provided that these studies are not intended for generating data to make a regulatory submission.\[14\]
• In the event that the IEC feels that there could be a potential overlap between the academic and regulatory purposes of the trial, they should notify the office of the DCGI. If the IEC does not hear from the DCGI within 30 days, it should be presumed that no permission is needed from the licensing authority

Obtain informed consent from participants
• Investigators must ensure that written, informed consent is obtained from all participants in a clinical trial
• For trials that involve vulnerable participants
(children or mentally challenged patients for example) and involve a new chemical entity or a new molecular entity, the investigators in addition have to ensure audio visual recording of the informed consent process (gazette notification dated 19th November, 2013).[10]

Report serious adverse events that occur during a clinical trial

- An SAE is defined as an untoward medical occurrence during a clinical trial that is associated with death, in patient hospitalisation (if the study was done on outpatient basis), prolongation of hospitalisation (if the study was conducted on in-patient basis), persistent or significant disability or incapacity, a congenital anomaly or birth defect or is otherwise life-threatening.[10] The timelines for reporting SAEs are given below
  - The investigator should report all SAEs to the DCGI (for regulatory studies), the sponsor and the IEC, within 24 h of their occurrence (for academic studies, these should be reported only to the IEC within 24 h)[20]
  - If unable to do so, the reason for delay in reporting the SAE along with the report should be submitted to the DCGI
  - Send SAE report to DCGI after due analysis. In addition, send to Chairman of IEC and the Head of the institution where the trial has been conducted within 14 calendar days of occurrence of the event
  - IEC should submit its report on the SAE, after due analysis, along with its opinion on the financial compensation (if any) to be paid by the sponsor or his representative, and to the DCGI within 30 calendar days of occurrence of the event
  - IEC should submit its report on the SAE, after due analysis, along with its opinion on the financial compensation (if any) to be paid by the sponsor or his representative, and to the DCGI within 30 calendar days of occurrence of the event

Understand that compensation for trial related death and injury is now required and the implications of compensation particularly when academic studies with ‘new drugs’ are carried out

Compensation in a clinical trial is needed both when death occurs or when there is clinical trial-related injury. The formulae for compensation for both are described below:[21]

- **Compensation for death:** \( B \times F \times R/99.37 \), where ‘B’ is a base amount of 8 lakhs, ‘F’ is an age factor based on the Workmen Compensation Act and ‘R’ a risk factor that takes into account the severity, duration of disease and co-morbidities

- **Compensation for permanent disability:** \( (C \times D \times 90)/(100 \times 100) \), where ‘C’ is the quantum of compensation which would have been given to the nominee in case of death of the participant and ‘D’ is the percentage disability suffered by the subject

- **Compensation for an SAE leading to life-threatening disease:** \( 2 \times W \times N \), where ‘W’ is the minimum wage per day of the unskilled worker (in Delhi) and ‘N’ is the number of days of hospitalisation

- **Compensation for birth defect or congenital anomaly:** Medical care to be provided as long as required and a lumpsum amount to be kept in a fixed deposit that would bring in a monthly interest equal to half of the minimum wage of an unskilled worker in Delhi

**Addressing SAEs and compensation:** For dealing with SAEs, some institutions have a SAE subcommittee (over and above the IEC) that meets regularly to review and evaluate SAEs. For institutes that do not have them, this would be a good committee to constitute. Since clinical trial related injury or death is equally possible both with pharmaceutical industry and investigator-initiated (academic) studies, budgetary provisions need to be in place at the institutional level for the medical management of adverse events [AEs], SAEs and provision of insurance to trial participants.

Site preparedness (rule 122DAC)

- Understand that the regulator can inspect the site at any time and that he can cancel the trial permission and discontinue the study. Therefore preparedness of the study site at all times must be ensured

Studies with medical devices

A draft notification [Medical Devices Rules, 2016] dated 17th October 2016, has been issued for medical devices by the Ministry of Health and Family Welfare, Department of Health and Family Welfare, Government of India [GSR 983 (E)]. Per this notification, medical devices are broadly classified as investigational medical devices and registered or approved medical devices. Chapter VII of this notification states that clinical trials with the former need both IEC and DCGI approval, while academic studies [studies not intended for manufacturing or marketing the device] with the latter, need only IEC approval.[22]
**Table 2: Key rules of the Drugs and Cosmetics Act and what they mean for the researcher**

<table>
<thead>
<tr>
<th>Rule number</th>
<th>What the rule covers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Must know rules</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Rule 122DA - Application for permission to conduct a clinical trial for new drug/investigational new drug | • Approval needs to be sought from the DCGI (Licensing Authority) to conduct a new drug trial  
- The application for grant of permission to conduct Phase-I, Phase-II and Phase-III trial on a new drug to be made along with a fee of Rs. 50,000/-, Rs. 25,000/- and Rs. 25,000/- respectively [use form 44]  
- No fee shall be required by Central Government or State Government Institutes involved in clinical research for conducting trials for academic or research purposes  
- No permission is needed from DCGI for the conduct of clinical trial intended for academic purposes in respect of approved drug formulation for any new indication, new route of administration or new dose or new dosage, if the trial has got the IEC approval |
| Rule 122DA - Definition of a clinical trial. Formerly, this definition came under rule 122DAA | • A clinical trial is defined as ‘a systematic study of new drug(s) in human subject(s) to generate data for discovering and/or verifying the clinical, pharmacological (including pharmacokinetic and pharmacodynamic) and/or adverse effects with the objective of determining the safety and/or efficacy of the new drug’ |
| Rule 122DAB - compensation in case of trial related injury or death | • Subjects are entitled to compensation for any injury or death arising due to:  
- Adverse effect of investigational product(s)  
- Scientific misconduct or negligence by the sponsor or investigator  
- Use of placebo in placebo-controlled trials where standard of care was not provided despite being available  
- Failure of investigational product to provide intended therapeutic effect [where standard of care was not provided despite being available]  
- Any procedures involved in the trial  
- In utero injury to a foetus due to participation of the parent in a trial  
- Adverse effects due to concomitant medication excluding standard of care  
- Free medical management should be given to the subject as long as required or till it is established that the injury is not related to the clinical trial, whichever is earlier  
- In case of any trial related injury or death, financial compensation should also be given, as per order of DCGI, over and above any expenses incurred on the medical management of the subject  
- If there is no permanent injury, the quantum of compensation should be commensurate with the nature of the non-permanent injury and loss of wages of the trial subjects  
- The sponsor (whether a pharmaceutical company or an institution) should give an undertaking to the Licensing Authority to provide compensation for any trial related injury or death |
| Rule 122DAC second amendment - permission to conduct clinical trial | • Clinical trial should be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice guidelines and other applicable regulations in India  
- An approval of the EC shall be obtained before initiation of the study  
- Trial registration is mandatory for regulatory studies/trials  
- Trial registration with CTRI before first patient is enrolled is mandatory  
- The CDSCO is authorised to inspect trial sites of sponsors and investigators  
- If non-compliance is found, the following actions can be taken - suspending the study permission, cancelling the trial permission, debarring the sponsor and/or investigator from conducting studies in the future  
- Annual status report is to be submitted to the office of the DCGI  
- SAE reporting should be as per prescribed timelines |
| Rule 122DD - Registration of ECs | • An IEC can review and accord its approval to a clinical trial protocol only if it is registered with the regulatory authority  
- EC registration has a 3 year validity only |
| Rule 122E - Definition of new drug | • One that has not been used in the country to any significant extent and has not been recognised as effective and safe by the regulatory authority  
- An already approved drug which is proposed to be marketed with new claims namely indications, dosage, dosage form (including sustained release formulation) and new route of administration  
- A fixed drug combination of two or more already approved drugs which is proposed to be combined for the first time in a fixed ratio  
- All vaccines and r-DNA derived drugs are considered new drugs  
- A new drug shall continue to be considered as new drug for a period of 4 years from the date of its first approval |

Contd...
Interventional studies in Anaesthesia that are not “drug” trials

Clinical studies/trials that are investigator-initiated and involve procedures as interventions [e.g., comparison of effectiveness of two different techniques of brachial plexus block] would need Institutional Ethics committee approval and CTRI registration.

Table 2 covers must know and good to know aspects of clinical trial research.

**SOURCES OF FUNDING FOR ACADEMIC INVESTIGATOR INITIATED RESEARCH**

Several governmental and non-governmental organisations within the country fund academic research and the academician needs to make an application to them with application formats and timelines being available on their home pages. Some of these include - ICMR, Department of Biotechnology, Department of Science and Technology and the Council for Scientific and Industrial Research. In addition, several pharmaceutical companies in the country also fund investigator initiated research. The funding from the industry could be by way of provision of drug supplies or monetary support or both. The control of the study including its conception, conduct and analysis remains exclusively with the investigator in these studies and would need a clear memorandum of understanding with the industry funder.

**WORKING WITH A COLLABORATOR OUTSIDE THE COUNTRY**

Studies that involve a collaborator from outside India need an additional approval from the Health Ministry Screening Committee, a committee that works out of ICMR and meets quarterly to assess these projects for collaborative merit.[23]

**THE ROAD AHEAD**

India accounts for 17% of the world’s population and 20% of the global disease burden expressed as disability adjusted life years.[24] The scope for clinical research in the country thus is enormous as it faces the dual burden of both communicable and non-communicable diseases.[25] A recent study has also shown that the regulatory studies done in the country are not commensurate with their health care needs.[26]

An understanding of both the disease burden coupled with the regulatory requirements by the researcher will go a long way in alleviating disease associated burden and suffering in the country.

**CONCLUSIONS**

The academic investigator needs to be up to speed in reading, understanding and applying regulations and work in tandem with the pharmaceutical industry for greater patient benefit. The ECs now have a larger...

---

**Table 2: Contd...**

<table>
<thead>
<tr>
<th>Rule number</th>
<th>What the rule covers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rule 122A - Application for permission to import a new drug</td>
<td>• A new drug can be imported only after obtaining permission from the DCGI • Application to be made in Form 44 along with a fee of Rs. 50,000/- • Data from local [Indian] clinical trials should be submitted if applicable • The DCGI may grant permission to import the new drug in public interest based on data/evidence generated outside the country</td>
</tr>
<tr>
<td>Rule 122B - Application for approval to manufacture a new drug</td>
<td>• Approval needs to be sought from the DCGI (Licensing Authority) to manufacture a new drug • Application to be made in Form 44 along with a fee of Rs. 50,000/- • Data from local [Indian] clinical trials should be submitted if applicable</td>
</tr>
<tr>
<td>Rule 122D - Permission to import or manufacture fixed dose combination (the import aspect of this rule is relevant to the researcher)</td>
<td>• Approval needs to be sought from the DCGI (Licensing Authority) to manufacture a fixed dose combination of two or more drugs • Application to be made in form 44 along with a fee of Rs. 15,000/-</td>
</tr>
<tr>
<td>Rule 122DB - Suspension or cancellation of approval</td>
<td>• In case of failure to comply with the conditions of permission or approval, the Licensing Authority will suspend or cancel the approval by an order stating the reason for the same (applicable for the importer or manufacturer)</td>
</tr>
<tr>
<td>Rule 122DC - Appeal</td>
<td>• On suspension or cancelation of approval, an appeal can be made to the central government within 60 days</td>
</tr>
</tbody>
</table>

IEC – Institutional Ethics Committee; r-DNA – Recombinant DNA; EC – Ethics Committee; CDSCO – Central Drugs Standard Control Organization; DCGI – Drugs Controller General of India
than ever onus need to appreciate and understand risk – benefit and to empower themselves through repeated training and use of standard operating procedures given that it is known that the quality of IEC review across the country remains variable.[27] Finally, the empowering of IECs by the regulator towards approving studies with ‘new’ drugs without the need for regulatory approval means that researchers, IECs and institutional administrators should have mechanisms in place for greater participant protection, assessment and analysis of SAEs and budgetary provisions in place for insurance and compensation of participants in these trials.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES